Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Pediatr Blood Cancer. 2024 Oct;71(10):e31201. doi: 10.1002/pbc.31201. Epub 2024 Jul 15.
Pneumocystis jirovecii pneumonia (PJP) in hematopoietic cell transplant (HCT) recipients can be prevented by efficient prophylaxis. We surveyed HCT centers in North America to assess their PJP prophylaxis practices. Most institutions used intravenous (IV) pentamidine (29.6%) or inhaled pentamidine (14.8%); 37% institutions changed from trimethoprim/sulfamethoxazole (TMP-SMX) to another medication after conditioning; and 44% administered no PJP prophylaxis during the pre-engraftment period. Most institutions avoided using TMP-SMX during the pre-engraftment period, mainly because of concerns about myelotoxicity, despite this being the preferred PJP prophylaxis agent. There is a need to evaluate the effects of TMP-SMX on engraftment.
造血细胞移植（HCT）受者中的卡氏肺孢子菌肺炎（PJP）可通过有效的预防来预防。我们调查了北美的 HCT 中心，以评估他们的 PJP 预防措施。大多数机构使用静脉内（IV）喷他脒（29.6%）或吸入喷他脒（14.8%）；37%的机构在调理后从复方磺胺甲噁唑（TMP-SMX）改为另一种药物；44%的机构在植入前期间不进行 PJP 预防。尽管 TMP-SMX 是首选的 PJP 预防药物，但大多数机构在植入前期间避免使用 TMP-SMX，主要是因为担心骨髓毒性。有必要评估 TMP-SMX 对植入的影响。
